EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors
A Phase 1/2, Open Label Trial to Investigate the Safety, Tolerability, and Preliminary Efficacy of EIS-12656 as Single Agent and in Combination With a Poly-ADP Ribose Polymerase (PARP) Inhibitor, Trastuzumab Deruxtecan (T-DXd), or Darolutamide in Patients With Specified Solid Tumors
This trial investigates a new drug, EIS-12656, in participants with specified advanced solid tumors carrying pre-specified mutations. The trial consists of a dose escalation part (Phase 1) and a dose expansion part (Phase 2).
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The trial is a Phase 1/2, open label, uncontrolled trial to investigate the safety and preliminary efficacy of EIS-12656 alone or in combination with a PARPi, T-DXd or darolutamide in patients with specified advanced or metastatic solid tumors with homologous recombination deficient (HRD) mutations.
In the Phase 1 dose escalation phase participants will receive ascending doses of EIS-12656 to evaluate the safety and tolerability and to determine an effective and safe dose for the Phase 2 part.
In the Phase 2 dose expansion phase participants will either receive EIS-12656 monotherapy at the recommended Phase 2 dose (RP2D) (Module 1) or EIS-12656 in combination with a PARPi (Module 2), or T-DXd (Modules 3), or darolutamide (Module 4). The objective is to evaluate the safety and tolerability and anti-tumor activity of EIS-12656 alone or in combination.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Adrian Schomburg
- Phone Number: +49 17621046886
- Email: adrian@eisbach.bio
Study Locations
-
-
Louisiana
-
Shreveport, Louisiana, United States, 71103
- Recruiting
- LSU Health Sciences Center- Shreveport
-
Principal Investigator:
- Sindhu Devarashetty, MD
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Recruiting
- Duke Cancer Institute
-
Principal Investigator:
- Rani Bansal, MD
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- MD Anderson Cancer Center
-
Principal Investigator:
- Timothy Yap, MD
-
-
Washington
-
Seattle, Washington, United States, 98109
- Recruiting
- Fred Hutchinson Cancer Center
-
Principal Investigator:
- Jennifer Specht, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Recurrent locally advanced or metastatic solid tumors
- Homologous recombination deficient mutations
- Progressed on at least on prior line of treatment or intolerant to additional effective standard therapy
- Measurable disease (RECIST 1.1 Criteria)
- Adequate organ and bone marrow function
- ECOG Performance Status 0 or 1
- Life expectancy > 3 months
Exclusion Criteria:
- History or evidence of any clinically relevant gastrointestinal disease
- Radiation therapy within ≤2 weeks
- Significant cardiovascular disease
- Uncontrolled, active, symptomatic brain metastases
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: EIS-12656 Dose Escalation
|
EIS-12656 tablets given daily |
|
Experimental: Dose Expansion Module 1 (EIS-12656 Monotherapy)
|
EIS-12656 tablets given daily |
|
Experimental: Dose Expansion Module 2 (EIS-12656 + PARPi)
EIS-12656 will be given in combination with PARPi |
EIS-12656 tablets given daily as per USPI/SmPC |
|
Experimental: Dose Expansion Module 3 (EIS-12656 + T-DXd)
EIS-12656 will be given in combination with Trastuzumab deruxtecan |
EIS-12656 tablets given daily as per USPI/SmPC
Other Names:
|
|
Experimental: Dose Expansion Module 4 (EIS-12656 + darolutamide + ADT)
EIS-12656 will be given in combination with darolutamide and androgen deprivation therapy (ADT) |
EIS-12656 tablets given daily as per USPI/SmPC |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number and percentage of participants experiencing treatment-emergent adverse events (TEAEs)
Time Frame: From screening until end of treatment follow-up (45 days after last dose) (up to 7 months)
|
Number and percentage of participants with adverse events, serious adverse events, adverse events of special interest including changes in safety lab parameters, physical examinations, vital signs, and electrocardiogram (ECG) |
From screening until end of treatment follow-up (45 days after last dose) (up to 7 months)
|
|
Number and percentage of participants experiencing a dose limiting toxicity (DLT) (dose escalation part only)
Time Frame: Within 21 days of first dose
|
A DLT is defined as an EIS-12656 related adverse event during the first treatment cycle that meets the criteria outlined in the study protocol |
Within 21 days of first dose
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maximum plasma concentration of EIS-12656 (Cmax)
Time Frame: At pre-defined intervals from pre-dose Day 1 to Day 29
|
The concentration of EIS-12656 in plasma will be determined (Cmax will be derived) |
At pre-defined intervals from pre-dose Day 1 to Day 29
|
|
Area under the curve (AUC0-24)
Time Frame: At pre-defined intervals from pre-dose Day 1 to Day 29
|
The AUC0-24 reflects the actual body exposure to drug over the last 24h dosing interval |
At pre-defined intervals from pre-dose Day 1 to Day 29
|
|
Time to maximum concentration (Tmax)
Time Frame: At pre-defined intervals from pre-dose Day 1 to Day 29
|
The concentration of EIS-12656 in plasma will be determined (Tmax will be derived) |
At pre-defined intervals from pre-dose Day 1 to Day 29
|
|
Overall Response Rate
Time Frame: From screening to disease progression (approximately 1 year)
|
Overall response rate defined as percentage of participants with the best overall response of confirmed CR or confirmed PR according to RECIST v1.1 |
From screening to disease progression (approximately 1 year)
|
|
Duration of Response
Time Frame: From screening to disease progression or death (approximately 1 year)
|
Time from first response to progression or death, as defined by RECIST 1.1 |
From screening to disease progression or death (approximately 1 year)
|
|
Progression Free Survival
Time Frame: From screening to disease progression or death (approximately 1 year)
|
Time from first dose of EIS-12656 to progression or death, as defined by RECIST 1.1 |
From screening to disease progression or death (approximately 1 year)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- EIS-12656C01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.